**Core tip:** The results of the present study show that astragalus polysaccharides combined with matrine exert a synergistic protective effect against ulcerative colitis and lung injury, which might be associated with regulating trefoil factor 3 expression.

INTRODUCTION
============

As a main form of inflammatory bowel disease (IBD), ulcerative colitis (UC) is characterized by chronic inflammation and ulcerative lesions in the intestinal mucosa\[[@B1],[@B2]\]. Clinical manifestations of UC mainly include persistent or recurrent diarrhea, stools with mucus, blood, and pus, abdominal pain, and various systemic symptoms\[[@B1],[@B2]\]. Recently, due to the changes in diet structure, living habits, and environments, the incidence and diagnosis rates of UC in China have increased year by year\[[@B3]\]. Despite the substantial progress in the diagnosis and treatment of UC, unsatisfactory therapeutic effects remain an issue due to complicated etiology and a high rate of recurrence\[[@B4]\]. Therefore, elucidating the underlying mechanism of and searching for effective therapeutic methods for UC are quite essential.

Previous studies have demonstrated that lung injury is closely involved in IBD, including UC, thus, the treatment for UC should be focused on large intestine and lung injury simultaneously\[[@B5]-[@B7]\]. In recent years, several traditional Chinese medicines (TCMs) have been evidenced to exert protective effects against UC\[[@B8]\] and lung diseases\[[@B9]\]. *Astragalus membranaceus* is a popular TCM that has been widely used for its anti-fatigue, anti-sepsis, anti-inflammation, anti-hypertension, and anti-tumor properties\[[@B10]\]. Astragalus polysaccharides (APS) are one of the primary bioactive ingredients extracted from *Astragalus membranaceus*, and play important roles in treating oxidative stress, immunological diseases, and cancers based on their pharmacological and biological effects\[[@B11],[@B12]\]. It has been shown that APS can attenuate experimental colitis by regulating the immune response\[[@B13],[@B14]\]. Also, APS are reported to protect against several lung diseases, such as pulmonary arterial hypertension\[[@B15]\] and chronic obstructive pulmonary disease\[[@B16]\]. Matrine, the extracts from another common TCM *Sophora flavescens Ait*., is also proved to be effective in treating colitis\[[@B17]\] and lung injury\[[@B18]\] due to its diverse pharmacological properties, including anti-virus, anti-inflammation, antioxidant, and anti-tumor activities\[[@B19]\]. However, few studies have investigated the effect of APS combined with matrine on UC and associated lung injury.

In the current study, we established a UC rat model by colon mucosal tissue sensitization combined with trinitro-benzene-sulfonic acid (TNBS)-ethanol, and then explored the effects and mechanisms of the treatments of salazopyrine, APS, matrine, and APS combined with matrine on histopathological changes of colon and lung tissues, intestinal mucosa injury, and lung injury in UC rats.

MATERIALS AND METHODS
=====================

Ethical approval
----------------

Approval from the Animal Ethics Committee of North China University of Science and Technology was obtained prior to experiments.

Preparation of antigen emulsion
-------------------------------

Totally, ten healthy male New Zealand white rabbits weighing 2.5 kg were obtained from Jinmuyang Laboratory Animal Breeding Co., Ltd (Beijing, China). The rabbits were sacrificed by air embolization, and then colon tissues were dissected and collected. The colonic mucosa tissue was scraped using a disinfecting blade, and added into the same amount of pre-cooled physiological saline to make the tissue homogenate. After centrifugation at 3000 rpm for 30 min at 4 °C, the supernatant was obtained and mixed with the same volume of complete Freund\'s adjuvant to prepare an antigen emulsion.

UC rat model
------------

UC was induced in rats by colon mucosal tissue sensitization combined with TNBS-ethanol. Briefly, the antigen emulsion (8 mg/each rat) was injected into the toes and groin of the rats on the 1st, 15th, and 22th days, respectively. On the 29th day, the rats were fasted with free access to water for 24 h, and then anesthetized with 10% chloral hydrate (0.35 mL/100g) by intraperitoneal injection. TNBS-50% ethanol was prepared by mixing TNBS solution (120 mg/mL) with 50% ethanol at a ratio of 1:1 (v/v). The rats were inverted, and then TNBS-50% ethanol was slowly injected into the intestine at 100 mg/kg body weight using a silicone tube inserted 8 cm proximal to the anus. After pinching the anus and keeping the anus elevated for 1 min, the rats were placed in the cage, with the buttock raised to prevent the drug outflow. The rats naturally awakened after the anesthetic failed.

Animal grouping, drug administration, and sample collection
-----------------------------------------------------------

A total of 150 healthy male Wistar rats (weighing 200 ± 10 g, purchased from Charles River, Beijing, China) were used for the following experiments after one week of acclimation. The grouping is shown as Figure [1](#F1){ref-type="fig"}. Briefly, 30 Wistar rats were randomly selected as a normal group, and the remaining 120 Wistar rats were induced as UC models. On the 3rd day after modeling, 10 rats in the normal group and 10 UC model rats were randomly selected and used for model validation by histopathological observation (0 wk). The remaining 105 UC model rats (five rats sacrificed after modeling) were randomly assigned to five groups: Model group (*n* = 25), salazopyrine control group (*n* = 25), APS treatment group (*n* = 15), matrine treatment group (*n* = 15), and monomer mixture group (*n* = 25). The rats in the salazopyrine group received 0.125 g/mL of salazopyrine (SASP, Sunve, Shanghai, China); rats in the APS treatment group were given 0.6 g/mL of APS (Fuzhou Rimian Technology Development Co. LTD, China); rats in the matrine treatment group were given 12 mg/mL of matrine (Xi\'an Linhe Biotechnology Co. LTD, China); and rats in the monomer mixture group were administered with the mixture of APS and matrine at a ratio of 1:1. All drugs in these groups were intragastrically administered at eight times of the dose for an adult human (60 kg body weight); and rats in the normal group and model group were intragastrically administered with equal volume of drinking water once a day. Among all the experimental animals, dynamic observation at 2 wk and 4 wk after administration was performed in the normal group, model group, salazopyrine control group, and monomer mixture group. Various indicators at 4 wk before and after the treatment were observed in the APS treatment group and matrine treatment group. Rats were anesthetized with 10% chloral hydrate (3.5 μL/g) by intraperitoneal injection, and lung and colon tissues were removed aseptically and stored in liquid nitrogen for the following experiments. Meanwhile, blood samples were collected from the abdominal aorta, and then serum was separated by centrifugation at 4 °C for 15 min and stored at ﹣80 °C.

![Flow chart of animal grouping. APS: Astragalus polysaccharides.](WJG-26-55-g001){#F1}

General indicators
------------------

The general conditions, including coating gloss, mental state, activity, diet, respiration, and feces, of rats at 0 wk, 2 wk, and 4 wk after administration in each group were observed. Meanwhile, body weight was measured, and disease activity index (DAI)\[[@B20]\] and colon mucosal damage index (CMDI)\[[@B21]\] were evaluated.

Histopathological assessment
----------------------------

Lung and colon tissues were fixed at 4 °C for 24 h with 4% paraformaldehyde. Following paraffin embedding, the tissues were sliced into sections. After dehydration with gradient ethanol, the sections underwent hematoxylin-eosin (HE) staining and mounting with neutral resin. Lastly, the sections were observed by light microscopy (Olympus, Japan).

Enzyme-linked immunosorbent assay
---------------------------------

Serum samples were thawed on ice, and then determined with a commercial enzyme-linked immunosorbent assay (ELISA) kit (Boster, Wuhan, China) for the content of endotoxin (ET). In addition, lung tissues in each group were cut into pieces, and then lung tissue homogenate was obtained with an ultrasonic cell disruptor (VCX130PB, Sonics, United States). After centrifugation at 4 °C for 15 min, the supernatant was determined with commercial ELISA kits (Boster) for the contents of tumor necrosis factor (TNF)-α, and interleukins (IL)-1β according to the manufacturer's instructions.

Diamine oxidase measurement
---------------------------

Diamine oxidase (DAO) activity in serum samples was detected by spec-trophotometry. Briefly, the standard curve of DAO was made. Then, 100 μL of serum samples were incubated with 1 mL of phosphate buffer, 50 μL of HPRO (200 μg), 50 μL of o-dianisidine (50 μg), and 50 μL of pentanediamine (1750 μg) for 1.5 h in a water bath at 37 °C. Lastly, 200 μL of mixture was added into 96-well plates, and the absorbance at 436 nm was read with a microplate reader (Molecular Devices, United States).

Myeloperoxidase, superoxide dismutase, and malondialdehyde activity detection
-----------------------------------------------------------------------------

Lung tissues were cut into pieces, and then lung tissue homogenate was obtained with an ultrasonic cell disruptor (VCX130PB, Sonics, United States). The activities of myeloperoxidase (MPO), superoxide dismutase (SOD), and malondialdehyde (MDA) were determined with MPO, SOD, and MDA detection kits (Nanjing Jiancheng Bioengineering Institute, China), respectively, according to the manufacturer's instructions.

Western blot analysis
---------------------

Lung and colon tissues were lysed with RIPA lysis buffer (Applygen, Beijing, United States), and protein was extracted by centrifugation and detected with the BCA kit (CW Biotech Co., Beijing, China). Then, protein samples were separated on an SDS-PAGE gel, and transferred to polyvinylidene fluoride membranes, followed by blockage with 5% nonfat milk for 1 h. Next, the membrane was incubated with anti-rat zonula occludens (ZO)-1 antibody (1:200, Santa Cruz, Santa Cruz, United States) or GAPDH antibody (Zhongshan Biotech, Beijing, China) overnight at 4 °C, and then washed with phosphate buffer saline, followed by the incubation with a secondary antibody (1:1000, Applygen, Beijing, United States) for 2 h at room temperature, respectively. Lastly, enhanced chemiluminescence (ECL, Millipore, United States) was used to detect the protein levels.

Immunohistochemistry
--------------------

Lung and colon tissues were fixed at 4 °C for 24 h with 4% paraformaldehyde. Following paraffin embedding, the tissues were sliced into sections. After dehydration with gradient ethanol, the sections were immunostained with Occludin (Abcam, Cambridge, MA, United States) or trefoil factor 3 (TFF3, ProSci, Poway, CA, United States) antibody, followed by staining with a secondary antibody (Zhongshan Biotech, Beijing, China), and incubation with diaminobenzidine (Zhongshan Biotech, Beijing, China). Ultimately, the sections were observed by light microscopy (Olympus, Japan).

Statistical analysis
--------------------

SPSS Statistics 20.0 software (IBM, Armonk, NY, United States) was used for data statistical analyses. Data are expressed as the mean ± SD. The differences between groups were analyzed by one-way ANOVA followed by multiple comparisons by the LSD test. *P* values \< 0.05 were considered statistically significant.

RESULTS
=======

Effect of APS combined with matrine on general conditions and histopathological changes in UC rats
--------------------------------------------------------------------------------------------------

The rats in the normal group showed smooth hair, sensitive response, high activity, normal diet, normal feces, and stable breathing, while the rats in the model group presented pale yellow color hair, lack of energy, sleepiness, decreased appetite, softened feces, and dyspnea. At 2 wk after administration, compared with the model group, rats in the salazopyrine control group had increased coating glossiness, less autonomic activity, and improved feces. Meanwhile, the mental state, activity, food intake, defecation, and respiratory symptoms of rats in the matrine treatment group, APS treatment group, and the monomer mixture group were also improved compared with the model group. In addition, these general conditions of rats were obviously improved at 4 wk than those at 2 wk. Moreover, the weight of rats in the model group was significantly lower than that in the normal group (*P* \< 0.01, Table [1](#T1){ref-type="table"}) at 0 wk. At 2 wk and 4 wk, compared with the control group, the weight of rats was also lower in the other groups, and the weight of rats was increased in comparison with rats at 0 wk, especially in the APS treatment group and the monomer mixture group (Table [1](#T1){ref-type="table"}). Compared with the normal group, DAI score was significantly increased in the model group (*P* \< 0.01, Table [2](#T2){ref-type="table"}) at 0 wk. Similarly, at 2 wk and 4 wk, DAI scores were also increased in the other groups compared with the normal group (Table [2](#T2){ref-type="table"}). However, rats in the other groups had lower DAI scores than the model group, especially in the APS treatment group and the monomer mixture group (Table [2](#T2){ref-type="table"}). Furthermore, HE staining revealed that the colonic mucosa of rats in the model group showed congestion, edema, ulceration, and a large amount of lymphocyte and neutrophil infiltration, and lung tissue of rats in the model group showed obvious congestion, edema, and a large amount of inflammatory cell infiltration (Figure [2](#F2){ref-type="fig"}). Nonetheless, compared with the model group, histopathological observation was improved in the other treatment groups at 2 wk and 4 wk after administration (Figure [2](#F2){ref-type="fig"}).

###### 

Body weight of rats in various groups

  **Group**              ***n***   **0 wk**                                         ***n***   **2 wk**                                         ***n***   **4 wk**
  ---------------------- --------- ------------------------------------------------ --------- ------------------------------------------------ --------- ------------------------------------------------
  Normal                 10        414.00 ± 29.28                                   10        467.50 ± 21.44                                   10        507.60 ± 49.21
  Model                  10        355.90 ± 25.60[b](#T1FN2){ref-type="table-fn"}   10        413.10 ± 27.91[b](#T1FN2){ref-type="table-fn"}   10        461.30 ± 37.54
  Salazopyrine control                                                              10        420.70 ± 35.29[b](#T1FN2){ref-type="table-fn"}   11        451.91 ± 38.31[b](#T1FN2){ref-type="table-fn"}
  Matrine treatment                                                                 13        429.23 ± 38.04[a](#T1FN1){ref-type="table-fn"}   12        458.83 ± 45.36[a](#T1FN1){ref-type="table-fn"}
  APS treatment                                                                     13        443.62 ± 45.06                                   13        486.92 ± 55.67
  Monomer mixture                                                                   13        426.92 ± 30.74[b](#T1FN2){ref-type="table-fn"}   12        489.75 ± 32.06

*P* \< 0.05 and

*P* \< 0.01 *vs* normal group. APS: Astragalus polysaccharides.

###### 

Disease activity indexes of rats in various groups

  **Group**              ***n***   **0 wk**                                      ***n***   **2 wk**                                                                      ***n***   **4 wk**
  ---------------------- --------- --------------------------------------------- --------- ----------------------------------------------------------------------------- --------- -----------------------------------------------------------------------------
  Normal                 10        0.00 ± 0.00                                   10        0.00 ± 0.00                                                                   10        0.00 ± 0.00
  Model                  10        3.00 ± 0.59[b](#T2FN2){ref-type="table-fn"}   10        1.67 ± 0.90[b](#T2FN2){ref-type="table-fn"}                                   10        1.13 ± 0.63[b](#T2FN2){ref-type="table-fn"}
  Salazopyrine control                                                           10        0.80 ± 0.53[a](#T2FN1){ref-type="table-fn"}                                   11        0.36 ± 0.35
  Matrine treatment                                                              13        0.51 ± 0.48[a](#T2FN1){ref-type="table-fn"}[c](#T2FN3){ref-type="table-fn"}   12        0.33 ± 0.45
  APS treatment                                                                  13        0.67 ± 0.47[b](#T2FN2){ref-type="table-fn"}                                   13        0.41 ± 0.34[a](#T2FN1){ref-type="table-fn"}
  Monomer mixture                                                                13        0.56 ± 0.48[a](#T2FN1){ref-type="table-fn"}[c](#T2FN3){ref-type="table-fn"}   12        0.56 ± 0.48[a](#T2FN1){ref-type="table-fn"}[c](#T2FN3){ref-type="table-fn"}

*P* \< 0.05 and

*P* \< 0.01 *vs* normal group;

*P* \< 0.05 *vs* model group. APS: Astragalus polysaccharides.

![Astragalus polysaccharides combined with matrine improve histopathological changes in rats with ulcerative colitis. A and B: Histopathological changes of colon (A) and lung tissues (B) in various groups analyzed by hematoxylin-eosin staining. APS: Astragalus polysaccharides.](WJG-26-55-g002){#F2}

Effect of APS combined with matrine on intestinal mucosa injury in UC rats
--------------------------------------------------------------------------

CMDI score was used to evaluate intestinal mucosa injury. Compared with the normal group, CMDI score was significantly elevated in the model group (*P* \< 0.01, Table [3](#T3){ref-type="table"}) at 0 wk. Consistently, CMDI scores were also increased in other groups compared with those in the normal group at 2 wk and 4 wk (Table [3](#T3){ref-type="table"}). However, rats in other treatment groups had lower CMDI scores than that in the model group, especially in the matrine treatment group and the monomer mixture group (Table [3](#T3){ref-type="table"}). In addition, compared with the normal group, serum ET levels were obviously increased in the model group at 0 wk, 2 wk, and 4 wk (*P* \< 0.05, Figure [3A](#F3){ref-type="fig"}), while lower serum ET levels were found in the other treatment groups than in the model group (Figure [3A](#F3){ref-type="fig"}). Similarly, the trend of DAO activity was consistent with ET level (Figure [3B](#F3){ref-type="fig"}).

###### 

Colon mucosal damage indexes of rats in various groups

  **Group**              ***n***   **0 wk**                                      ***n***   **2 wk**                                                                      ***n***   **4 wk**
  ---------------------- --------- --------------------------------------------- --------- ----------------------------------------------------------------------------- --------- -----------------------------------------------------------------------------
  Normal                 10        0.00 ± 0.00                                   10        0.00 ± 0.00                                                                   10        0.00 ± 0.00
  Model                  10        6.70 ± 1.89[b](#T3FN2){ref-type="table-fn"}   10        6.40 ± 1.78[b](#T3FN2){ref-type="table-fn"}                                   10        4.70 ± 2.06[b](#T3FN2){ref-type="table-fn"}
  Salazopyrine control                                                           10        3.90 ± 2.23[b](#T3FN2){ref-type="table-fn"}                                   11        4.00 ± 2.24[b](#T3FN2){ref-type="table-fn"}
  Matrine treatment                                                                                                                                                      12        1.83 ± 1.59[a](#T3FN1){ref-type="table-fn"}[c](#T3FN3){ref-type="table-fn"}
  APS treatment                                                                                                                                                          13        2.33 ± 1.97[a](#T3FN1){ref-type="table-fn"}
  Monomer mixture                                                                11        0.56 ± 0.48[a](#T3FN1){ref-type="table-fn"}[c](#T3FN3){ref-type="table-fn"}   12        1.92 ± 1.73[a](#T3FN1){ref-type="table-fn"}[c](#T3FN3){ref-type="table-fn"}

*P* \< 0.05 and

*P* \< 0.01 *vs* normal group;

*P* \< 0.05 *vs* model group. APS: Astragalus polysaccharides.

![Astragalus polysaccharides combined with matrine inhibit diamine oxidase activity in rats with ulcerative colitis. A: Serum endotoxin levels in various groups detected by enzyme-linked immunosorbent assay; B: Serum diamine oxidase activity in various groups detected by spectrophotometry. ^a^*P* \< 0.05 and ^b^*P* \< 0.01 *vs* normal group; ^c^*P* \< 0.05 and ^d^*P* \< 0.01 *vs* model group. APS: Astragalus polysaccharides; ET: Endotoxin; DAO: Diamine oxidase.](WJG-26-55-g003){#F3}

Effect of APS combined with matrine on the expression of ZO-1 and Occludin in lung and colon tissues of UC rats
---------------------------------------------------------------------------------------------------------------

Western blot analysis showed that ZO-1 protein expression in colon tissues was significantly decreased in the model group at 2 wk and 4 wk compared with the normal group (*P* \< 0.05, Figure [4A](#F4){ref-type="fig"}), while ZO-1 protein expression in colon tissues was increased in the other treatment groups than in the model group, especially in the monomer mixture group at 4 wk (*P* \< 0.05, Figure [4A](#F4){ref-type="fig"}). Similarly, in lung tissues, ZO-1 protein expression was obviously decreased in the model group at 2 wk and 4 wk compared with the normal group (*P* \< 0.01, Figure [4B](#F4){ref-type="fig"}); however, the other treatment groups showed increased protein expression of ZO-1 compared with the model group, especially in the monomer mixture group at 2 wk (*P* \< 0.05, Figure [4B](#F4){ref-type="fig"}). Moreover, immunohistochemistry analysis revealed that Occludin was usually expressed in intestinal mucosal epithelial cells and glandular cells in colon tissues in normal rats. Occludin protein expression in colon tissues was remarkably decreased in the model group at 2 wk and 4 wk compared with the normal group (*P* \< 0.05, Figure [4C](#F4){ref-type="fig"}), while Occludin protein expression in colon tissues was increased in the other treatment groups than in the model group, especially in the APS treatment group and monomer mixture group at 4 wk (*P* \< 0.05, Figure [4C](#F4){ref-type="fig"}). In addition, Occludin was usually expressed in alveolar epithelial cell membrane in lung tissues of normal rats. Consistently, in lung tissues, Occludin protein expression at 2 wk and 4 wk was prominently decreased in the model group compared with the normal group (*P* \< 0.05, Figure [4D](#F4){ref-type="fig"}); however, the other treatment groups showed increased protein expression of Occludin compared with the model group, especially in the APS treatment group and monomer mixture group at 4 wk (*P* \< 0.05, Figure [4D](#F4){ref-type="fig"}).

![Astragalus polysaccharides combined with matrine inhibit the expression of zonula occludens-1 and Occludin in lung and colon tissues of rats with ulcerative colitis. A and B: Zonula occludens-1 (ZO-1) expression in colon (A) and lung tissues (B) in various groups detected by Western blot analysis; C and D: Occludin expression in colon (C) and lung tissues (D) in various groups detected by immunohistochemistry analysis. ^a^*P* \< 0.05 and ^b^*P* \< 0.01 *vs* normal group; ^c^*P* \< 0.05 and ^d^*P* \< 0.01 *vs* model group. APS: Astragalus polysaccharides; ZO-1: Zonula occludens-1; N: Normal group; M: Model group; SC: Salazopyrine control group; MT: Matrine treatment group; AT: Astragalus polysaccharides treatment group; MM: Monomer mixture group.](WJG-26-55-g004){#F4}

Effect of APS combined with matrine on inflammatory response and oxidative stress injury in ling tissues of UC rats
-------------------------------------------------------------------------------------------------------------------

ELISA showed that the expression of inflammatory factors such as TNF-α and IL-1β in lung tissues was significantly increased in the model group at 2 wk and 4 wk compared with the normal group (*P* \< 0.05, Figure [5A](#F5){ref-type="fig"} and [B](#F5){ref-type="fig"}), while their expression was decreased in the other treatment groups compared with the model group (*P* \< 0.05, Figure [4A](#F4){ref-type="fig"} and [B](#F4){ref-type="fig"}). In addition, in lung tissues, SOD activity was obviously decreased in the model group at 2 wk and 4 wk compared with the normal group (*P* \< 0.01, Figure [5C](#F5){ref-type="fig"}); however, the other treatment groups showed an increased activity of SOD compared with the model group, especially at 4 wk (*P* \< 0.05, Figure [5C](#F5){ref-type="fig"}). Furthermore, the activities of MDA and MPO were conspicuously enhanced in the model group at 2 wk and 4 wk compared with the normal group (*P* \< 0.05, Figure [5D and E](#F5){ref-type="fig"}); however, the activities of MDA and MPO were weakened in the other treatment groups compared with the model group (Figure [5D](#F5){ref-type="fig"} and [E](#F5){ref-type="fig"}).

![Astragalus polysaccharides combined with matrine relieve inflammatory response and oxidative stress injury in lung tissues of rats with ulcerative colitis. A and B: Tumor necrosis factor-α (A) and interleukin-1β levels (B) in lung tissues in various groups detected by enzyme-linked immunosorbent assay (ELISA); C-E: Activities of superoxide dismutase (C), malondialdehyde (D), and myeloperoxidase (E) in lung tissues in various groups determined with commercial detection kits. ^a^*P* \< 0.05 and ^b^*P* \< 0.01 *vs* normal group; ^c^*P* \< 0.05 and ^d^*P* \< 0.01 *vs* model group. APS: Astragalus polysaccharides; TNF-α: Tumor necrosis factor-α; IL-1β: Interleukins-1β; MPO: Myeloperoxidase.](WJG-26-55-g005){#F5}

Effect of APS combined with matrine on TFF3 expression in lung and colon tissues of UC rats
-------------------------------------------------------------------------------------------

Immunohistochemistry analysis revealed that TFF3 was usually expressed in intestinal mucosa goblet cells and intestinal gland acini in colon tissues of normal rats. TFF3 protein expression in colon tissues was remarkably decreased in the model group at 2 wk and 4 wk compared with the normal group (*P* \< 0.05, Figure [6A](#F6){ref-type="fig"}), while TFF3 protein expression in colon tissues was increased in the other treatment groups compared with the model group, especially in the monomer mixture group at 2 wk and 4 wk (*P* \< 0.05, Figure [6A](#F6){ref-type="fig"}). In addition, compared with the salazopyrine control group, TFF3 protein expression in colon tissues was higher in the monomer mixture group at 4 wk (*P* \< 0.05, Figure [6A](#F6){ref-type="fig"}). Similarly, in lung tissues, TFF3 protein expression was decreased in the model group at 2 wk and 4 wk compared with the normal group, but without a significant difference (Figure [6B](#F6){ref-type="fig"}). Meanwhile, increased protein expression of TFF3 was found in the APS treatment group and monomer mixture group at 4 wk compared with the model group without a significant difference (Figure [6B](#F6){ref-type="fig"}).

![Astragalus polysaccharides combined with matrine increase trefoil factor 3 expression in lung and colon tissues of rats with ulcerative colitis. A and B: Trefoil factor 3 (TFF3) expression in colon (A) and lung tissues (B) in various groups detected by immunohistochemistry analysis. ^a^*P* \< 0.05 *vs* normal group; ^c^*P* \< 0.05 *vs* model group; ^e^*P* \< 0.05 *vs* salazopyrine control group. APS: Astragalus polysaccharides; TFF3: Trefoil factor 3.](WJG-26-55-g006){#F6}

DISCUSSION
==========

In the present study, a UC rat model was successfully established by colon mucosal tissue sensitization combined with TNBS-ethanol. The treatments of salazopyrine, APS, matrine, or APS combined with matrine inhibited DAI scores, increased body weight, and improved histopathological changes of colon and lung tissues in UC rats. In addition, the treatments of salazopyrine, APS, matrine, or APS combined with matrine alleviated intestinal mucosa injury and inhibited ET levels and DAO activity in UC rats. Moreover, in lung tissues, the inflammatory response and oxidative stress injury were relieved after the treatments of salazopyrine, APS, matrine, or APS combined with matrine in UC rats. Furthermore, the results revealed that the expression of ZO-1, Occludin, and TFF3 in lung and colon tissues was increased after different treatments in UC rats. Notably, APS combined with matrine exerted a better protective effect against UC and lung injury compared with other treatments.

The roles of APS and matrine have been widely investigated in various diseases. Previous studies have demonstrated that APS can significantly improve histological and DAI scores, and increase body weight by regulating the inflammatory response in dextran sulfate sodium-induced colitis\[[@B22],[@B23]\]. It is also reported that matrine can ameliorate colitis by regulating the inflammatory response\[[@B17],[@B24]\]. These results are consistent with our findings. Meanwhile, CMDI, ET levels, and DAO activity were detected in this study. CMDI is a common indicator to evaluate intestinal mucosa injury in colitis, and a high CMDI score represents a serious degree of intestinal mucosa injury\[[@B25],[@B26]\]. In addition, ET is a lipopolysaccharide that is present in the cell wall of Gram-negative bacteria, and is particularly accumulated in the intestine\[[@B27]\]. The healthy human intestinal barrier can protect ET from entering the blood circulation, while the dysfunctional intestinal barrier causes ET to pass through the intestinal mucosa and enter the blood circulation, thereby resulting in endotoxemia\[[@B28],[@B29]\]. DAO is present in the mucosa or villi of mammals, and is normally abundant in intestinal mucosa, kidney, and placental tissues, but rarely in serum\[[@B30]\]. After intestinal mucosal epithelial damage, the cytoplasm DAO can be released into the blood circulation\[[@B30],[@B31]\]. Therefore, serum ET level and DAO activity are ideal indicators reflecting the structure and function of the intestinal mucosa. This study revealed that the treatments of APS or/and matrine inhibited CMDI scores, ET levels, and DAO activity in UC rats, indicating that they can alleviative intestinal mucosa injury. Moreover, the dysfunctional intestinal barrier is closely related to the tight junctions between cells\[[@B32]\]; thus, the expression of tight junction-associated proteins ZO-1 and Occludin in colon tissues was determined in this study. The tight junction mainly consists of the ZO protein family, Occludin protein, Claudin protein, and connective adhesion molecules, which is an important structure for maintaining mucosal permeability\[[@B33]\]. Occludin can interact with the intracellular protein ZO-1, and then bind to the backbone protein\[[@B33]\]; thus, ZO-1 and Occludin play important roles in performing tight junction barrier functions. Several studies have suggested that both ZO-1 and occludin were lowly expressed during colitis\[[@B34],[@B35]\], which is consistent with our study. Taken together, these results suggest that APS combined with matrine might exert a synergistic protective effect against UC.

It is well known that the inflammatory response and oxidative stress are involved in the pathophysiology of lung injury\[[@B36]\]. This study detected the expression of inflammatory factors such as TNF-α and IL-1β in lung tissues. Accumulating evidence has indicated that TNF-α and IL-1β levels were significantly elevated during lung injury\[[@B37],[@B38]\], which is consistent with our results. In addition, the activities of SOD, MDA, and MPO in lung tissues were measured in this study, which are most representative and important indicators during the oxidation-antioxidant balance systems\[[@B39]\]. A previous study has confirmed the widespread abnormality of oxygen free radical metabolism in UC\[[@B40]\]. UC contributes to increased permeability of the intestinal mucosa and elevated oxygen consumption, then a large number of O~2~^-^, OH, and lipid peroxides are produced, which damage the intestinal mucosa\[[@B40]\]. In addition, the oxygen free radical produced in UC can destroy lung tissue, thereby leading to inflammatory injury of the lungs\[[@B40]\]. This study revealed that SOD activity in lung tissues was obviously decreased, and the activities of MDA and MPO in lung tissues were conspicuously enhanced during UC, which indicated that UC was accompanied with lung injury. The anti-inflammatory role of APS and matrine has also been reported. Consistently, this study showed that the treatments of APS or/and matrine inhibited the levels of TNF-α and IL-1β, reduced the activities of MDA and MPO, and increased SOD activity. All these results indicated that APS combined with matrine might exert a synergistic protective effect against lung injury by regulating the inflammatory response and oxidative stress.

Furthermore, this study detected TFF3 expression in lung and colon tissues after different treatments in UC rats. The TFF family are a kind of small molecule polypeptides, and play roles in mucosal protection, inhibition of inflammatory mediators, regulation of cellular immunity, and apoptosis\[[@B41]\]. TFF3 is specifically distributed in the surface of the intestinal mucosa, and is confirmed to be closely related with the onset of UC\[[@B42]\]. It is generally believed that the expression of TFF3 is down-regulated during the acute onset of IBD, while the up-regulated expression of TFF3 is found during the recovery phase\[[@B43],[@B44]\]. Thus, TFF3 not only has a protective effect on the intestinal mucosal barrier, but its reduction is also related to the progression of UC. This study found decreased expression of TFF3 in UC rats at 2 wk and 4 wk, indicating that the down-regulation of TFF3 reduced the protective and repairing effects on the mucosa, promoted the formation of ulcers, and slowed the repair of damaged mucosa. After 2 wk and 4 wk of treatment with APS and matrine, the expression of TFF3 increased, suggesting that APS combined with matrine might increase the expression of TFF3, and then promote intestinal mucosal injury repair and protect intestinal mucosal barrier function. Therefore, we speculated that the synergistic protective effect of APS and matrine against UC and lung injury might be associated with regulating TFF3 expression.

In conclusion, APS combined with matrine exert a synergistic protective effect against UC and lung injury, which might be associated with regulating TFF3 expression.
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Research background
-------------------

Astragalus polysaccharides (APS) are bioactive components extracted from the radix of *Astragalus membranaceus*, a commonly used herbal compound in traditional Chinese medicine.

Research motivation
-------------------

APS was reported to have anti-inflammatory, anti-oxidative, anti-tumor, and anti-diabetic properties.

Research objectives
-------------------

To evaluate the therapeutic effect of APS and its potential mechanisms in a ulcerative colitis (UC) rat model induced by colon mucosal tissue sensitization combined with trinitro-benzene-sulfonic acid-ethanol.

Research methods
----------------

First, we used two groups of Wistar rats: UC models and controls. Then, 105 UC model rats were randomly divided to five groups: Model group (*n* = 25), salazopyrine control group (*n* = 25), APS treatment group (*n* = 15), matrine treatment group (*n* = 15), and monomer mixture group (*n* = 25).

Research results
----------------

The inflammatory response and oxidative stress injury was relieved in colitis observed in APS combined with matrine-treated mice.

Research conclusions
--------------------

APS combined with matrine may represent a potential therapeutic approach for treating inflammatory bowel disease.

Research perspectives
---------------------

Drug research can provide a valuable resource to help clinicians make strategic treatment choices that will ultimately benefit patients at many levels.
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